Cargando…

A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease

The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to v...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Julie, Schmidt, Signe Tandrup, Trebbien, Ramona, Cox, Rebecca Jane, Zhou, Fan, Follmann, Frank, Pedersen, Gabriel Kristian, Christensen, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836410/
https://www.ncbi.nlm.nih.gov/pubmed/35163772
http://dx.doi.org/10.3390/ijms23031850
_version_ 1784649672044838912
author Zimmermann, Julie
Schmidt, Signe Tandrup
Trebbien, Ramona
Cox, Rebecca Jane
Zhou, Fan
Follmann, Frank
Pedersen, Gabriel Kristian
Christensen, Dennis
author_facet Zimmermann, Julie
Schmidt, Signe Tandrup
Trebbien, Ramona
Cox, Rebecca Jane
Zhou, Fan
Follmann, Frank
Pedersen, Gabriel Kristian
Christensen, Dennis
author_sort Zimmermann, Julie
collection PubMed
description The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF(®)09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective.
format Online
Article
Text
id pubmed-8836410
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88364102022-02-12 A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease Zimmermann, Julie Schmidt, Signe Tandrup Trebbien, Ramona Cox, Rebecca Jane Zhou, Fan Follmann, Frank Pedersen, Gabriel Kristian Christensen, Dennis Int J Mol Sci Article The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF(®)09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective. MDPI 2022-02-06 /pmc/articles/PMC8836410/ /pubmed/35163772 http://dx.doi.org/10.3390/ijms23031850 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zimmermann, Julie
Schmidt, Signe Tandrup
Trebbien, Ramona
Cox, Rebecca Jane
Zhou, Fan
Follmann, Frank
Pedersen, Gabriel Kristian
Christensen, Dennis
A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
title A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
title_full A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
title_fullStr A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
title_full_unstemmed A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
title_short A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
title_sort novel prophylaxis strategy using liposomal vaccine adjuvant caf09b protects against influenza virus disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836410/
https://www.ncbi.nlm.nih.gov/pubmed/35163772
http://dx.doi.org/10.3390/ijms23031850
work_keys_str_mv AT zimmermannjulie anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT schmidtsignetandrup anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT trebbienramona anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT coxrebeccajane anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT zhoufan anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT follmannfrank anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT pedersengabrielkristian anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT christensendennis anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT zimmermannjulie novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT schmidtsignetandrup novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT trebbienramona novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT coxrebeccajane novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT zhoufan novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT follmannfrank novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT pedersengabrielkristian novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease
AT christensendennis novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease